Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

Pharmacogenomics

Volumn 14, Issue 11, 2013, Pages 1295-1304

  De Keyser, Catherine E ^a,b   Becker, Matthijs L ^a   Uitterlinden, André G ^a,c   Hofman, Albert ^a,c   Lous, Jan J ^d   Elens, Laure ^a,e   Visser, Loes E ^a   Van Schaik, Ron Hn ^a   Stricker, Bruno H ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate of Health Care   (Netherlands)

^c NETHERLANDS GENOMICS INITIATIVE   (Netherlands)

^d STAR Medical Diagnostic Center   (Netherlands)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

CYP3A4; HMG CoA reductase inhibitors; pharmacogenetics; PPARA; rs4253728 G>A; rs4823613 A>G; statins

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CYP3A4 GENE; CYP3A5 GENE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PPARA GENE; PROSPECTIVE STUDY; AGED; ALLELE; BLOOD; GENETICS; METABOLISM; MIDDLE AGED;

AGED; ALLELES; CHOLESTEROL; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; PPAR ALPHA; SIMVASTATIN;

EID: 84882240801     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.112     Document Type: Article

References (46)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994).
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301-1307 (1995).
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339(19), 1349-1357 (1998).
4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
5. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin. Cardiol. 21(4), 400-404 (2006).
6. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
7. Davidson MH, Maki KC, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96(4), 556-563 (2005).
8. Yan AT, Yan RT, Tan M et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am. J. Med. 119(8), 676-683 (2006).
9. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr. Opin. Lipidol. 18(4), 409-414 (2007).
10. Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr. Opin. Mol. Ther. 10(6), 555-561 (2008).
11. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112(1), 71-105 (2006).
12. Schmitz G, Drobnik W. Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin. Chem. Lab. Med. 41(4), 581-589 (2003).
13. Zineh I, Johnson JA. Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Expert Opin. Pharmacother. 7(11), 1417-1427 (2006).
14. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet. 47(7), 463-474 (2008).
15. Vickers S, Duncan CA, Vyas KP et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 18(4), 476-483 (1990).
16. Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 25(10), 1191-1199 (1997).
17. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol. 56(1), 120-124 (2003).
18. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
19. Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12), 861-866 (2011).
20. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93(1), 104-107 (2004).
21. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol. Drug Saf. 19(1), 75-81 (2010).
22. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47(1), 87-93 (2007).
23. Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8), 523-525 (2004).
24. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
25. Miao J, Jin Y, Marunde RL et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 9(5), 319-326 (2009).
26. Zeigler-Johnson C, Friebel T, Walker AH et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64(22), 8461-8467 (2004).
27. Klein K, Thomas M, Winter S et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91(6), 1044-1052 (2012).
28. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol. 7(4), 403-422 (1991).
29. Hofman A, van Duijn CM, Franco OH et al. The Rotterdam Study: 2012 objectives and design update. Eur. J. Epidemiol. 26(8), 657-686 (2011).
30. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16(3), 1215 (1988).
31. Richards JB, Rivadeneira F, Inouye M et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371(9623), 1505-1512 (2008).
32. Fruchart JC. Peroxisome proliferator-activated receptor-a (PPARa): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205(1), 1-8 (2009).
33. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-a activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10(3), 245-257 (1999).
34. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 405(6785), 421-424 (2000).
35. Shin MJ, Kanaya AM, Krauss RM. Polymorphisms in the peroxisome proliferator activated receptor a gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 198(2), 313-319 (2008).
36. Reinhard W, Stark K, Sedlacek K et al. Association between PPARa gene polymorphisms and myocardial infarction. Clin. Sci. (Lond.) 115(10), 301-308 (2008).
37. Flavell DM, Pineda Torra I, Jamshidi Y et al. Variation in the PPARa gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43(5), 673-680 (2000).
38. Jamshidi Y, Montgomery HE, Hense HW et al. Peroxisome proliferator-activated receptor a gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105(8), 950-955 (2002).
39. Tai ES, Demissie S, Cupples LA et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 22(5), 805-810 (2002).
40. Vohl MC, Lepage P, Gaudet D et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 41(6), 945-952 (2000).
41. Flavell DM, Jamshidi Y, Hawe E et al. Peroxisome proliferator-activated receptor a gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105(12), 1440-1445 (2002).
42. Hu M, Mak VW, Xiao Y, Tomlinson B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics 14(1), 25-34 (2013).
43. Thomas M, Burk O, Klumpp B et al. Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor a (PPARa). Mol. Pharmacol. 83(3), 709-718 (2013).
44. Hansten PD. Possible risks to patients receiving statins combined with other medications. J. Am. Coll. Cardiol. 41(3), 519-520 (2003).
45. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41(5), 343-370 (2002).
46. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466(7307), 707-713 (2010).